Telix Pharmaceuticals, based in Melbourne, Australia, has joined forces with Subtle Medical to incorporate the company’s AI-powered SubtlePET software into Illuccix, Telix’s imaging agent used in PET scanning for prostate cancer screening. This collaboration aims to enhance the accuracy and efficiency of prostate cancer screening through the use of advanced technology.
SubtlePET’s deep-learning algorithm has the potential to reduce the time required for PET scanning by up to 75%. The software is designed to seamlessly integrate into existing imaging center workflows, regardless of the PET scanner’s manufacturer or model. This innovation represents a significant advancement in the field of prostate cancer screening, offering a more streamlined and effective approach to detecting and monitoring the disease.
Illuccix (TLX591-CDx) is a radiopharmaceutical imaging agent that utilizes the radioactive isotope Gallium-68 for PET imaging of prostate-specific membrane antigen (PSMA) in patients with prostate cancer. This imaging agent received approval from the US Food and Drug Administration (FDA) in December 2021, highlighting its efficacy and safety in clinical practice.
Subtle Medical’s SubtlePET AI software, which enhances PET images, has already obtained CE mark in the EU and 510(k) clearance from the FDA in 2018. By integrating this cutting-edge technology into the Illuccix platform, Telix aims to offer a comprehensive and state-of-the-art solution for prostate cancer screening.
Telix CEO Kevin Richardson expressed his enthusiasm about the partnership, stating that the incorporation of SubtlePET into the Illuccix value proposition will enhance the company’s AI toolkit and solidify Illuccix’s reputation as a top-tier PSMA-PET imaging agent. This collaboration represents a significant step forward in the development of innovative solutions for prostate cancer diagnosis and treatment.
In addition to its partnership with Subtle Medical, Telix has a robust pipeline of products focused on prostate cancer. GlobalData’s Medical Device Intelligence Centre reports that Telix currently has five other products in development for prostate cancer, highlighting the company’s commitment to advancing the field of oncology imaging.
The global market for PET imaging systems is projected to grow significantly in the coming years, with a forecasted valuation of around $547 million by 2033. Similarly, the market for Gallium-68-based PET imaging agents is expected to reach $10.5 million by 2033, reflecting the increasing demand for advanced imaging technologies in the healthcare industry.
Overall, Telix’s collaboration with Subtle Medical represents a significant advancement in the field of prostate cancer screening, offering a cutting-edge solution that combines AI technology with innovative imaging agents. This partnership has the potential to revolutionize the way prostate cancer is detected and monitored, ultimately improving patient outcomes and enhancing the quality of care in oncology practice.
